Agenus Announces Virtual Annual Shareholders Meeting

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary

Agenus, a leading immuno-oncology company, has announced its Annual Shareholders Meeting will be held virtually on June 11, 2024, at 10:30 a.m. ET. Registration starts at 10:15 a.m. ET. Shareholders can participate by visiting and entering a 16-digit control number from their proxy materials. Guests can listen without a control number. Agenus focuses on cancer immunotherapy using a broad range of antibody therapeutics, adoptive cell therapies, and adjuvants. The company is headquartered in Lexington, MA, and more information can be found at

  • Virtual format allows broader access to shareholders.
  • Meeting scheduled for June 11, 2024, well in advance, providing ample notice.
  • Focus on cancer immunotherapy, a growing and high-impact field.
  • Utilization of a broad repertoire of therapeutic approaches, enhancing the potential for treatment success.
  • Virtual-only format may reduce engagement for shareholders who prefer in-person meetings.
  • No new financial or clinical updates provided in the announcement, limiting information on the company's progress.
  • Potential technical issues with virtual meetings could hinder participation.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit and enter the 16-digit control number found in their proxy materials. Guests may also access the Annual Shareholders Meeting, but in listen-only mode. No control number is required for guests.

Webcast Information:

Date: Tuesday, June 11, 2024

Time: 10:30 a.m. ET

A live webcast and replay will be accessible on the Company’s website at and at

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.





Source: Agenus Inc.


When is the Agenus virtual Annual Shareholders Meeting?

The Agenus virtual Annual Shareholders Meeting is on June 11, 2024, at 10:30 a.m. ET.

How can shareholders participate in the Agenus Annual Shareholders Meeting?

Shareholders can participate by visiting and entering their 16-digit control number from proxy materials.

Can guests attend the Agenus Annual Shareholders Meeting?

Yes, guests can attend in listen-only mode without a control number.

What is the focus of Agenus as a company?

Agenus focuses on discovering and developing immunological agents to treat cancers and infectious diseases.

Where is Agenus headquartered?

Agenus is headquartered in Lexington, MA.

Agenus Inc.


AGEN Rankings

AGEN Latest News

AGEN Stock Data

Biological Product (except Diagnostic) Manufacturing
United States of America